Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Status:
Terminated
Trial end date:
2019-06-04
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well cabazitaxel and prednisone work in treating patients
with hormone-resistant prostate cancer that has spread to other parts of the body. Drugs used
in chemotherapy, such as cabazitaxel and prednisone, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading.